Foundayo goes on sale in the UK by private prescription

Eli Lilly began UK supply of Foundayo, known chemically as orforglipron, on August 24, 2026, making Britain the first country in Europe where the oral obesity and diabetes drug is available ^[3][4]. The launch follows authorization by the UK's Medicines and Healthcare products Regulatory Agency on August 10, which made the UK the first regulator in Europe to approve the tablet for weight management and type 2 diabetes ^[6][3].

For now, access in the UK runs through private prescription only. Lilly said the pill will likely be priced between £100 and £120 a month, converting to roughly $136 to $164 ^[3]. That is well below the £330 monthly price Lilly charges for its Mounjaro injection in the UK ^[3]. NHS coverage is a separate matter entirely. England's National Institute for Health and Care Excellence, known as NICE, must complete its own cost-effectiveness review before the pill can be prescribed through the state health system ^[3][6]. A NICE spokesperson said the agency has requested more information from Lilly following its first committee meeting and has not set a date for a second review ^[3].

Foundayo is authorized in the UK for adults with a body mass index of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition, alongside diet and exercise changes ^[6]. It is also authorized to help control blood sugar in people with type 2 diabetes whose levels are not well managed ^[6]. The tablet is taken once a day, at any time, with no food or water restrictions, and dosing climbs through six steps from 0.8 mg up to 17.2 mg, with at least a month spent at each level ^[6]. The most common side effects reported are nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain ^[6].

The drug's chemistry is what makes this launch notable beyond one country's market. Orforglipron is a small-molecule GLP-1 receptor agonist, unlike semaglutide and tirzepatide, which are peptides broken down by digestion and normally require injection ^[1]. As a small molecule, orforglipron survives the gut intact, which is why it can be taken as a pill without the fasting rules that apply to oral semaglutide, sold as Rybelsus for diabetes and recently as a Wegovy pill for weight loss in the UK ^[2][1].

Why it matters for patients

For US readers, the UK rollout is a preview of how pricing and access questions may play out here. Foundayo was already approved by the FDA for obesity in April 2026, and Lilly submitted it for type 2 diabetes in the US during the second quarter of 2026 ^[1]. In the US, self-pay prices for Foundayo start at $149 a month and can rise to $349 for higher doses, while a Medicare pilot program offers some patients access for $50 a month ^[3].

The UK situation illustrates a pattern that also applies in the US: regulatory approval of a drug does not guarantee insurance or public coverage. In Britain, Foundayo can legally be prescribed now, but only those willing to pay privately can get it while NICE conducts its separate evaluation ^[3][6]. American patients face a similar two-step process, where FDA approval determines legal availability but insurers, employers and Medicare separately decide what they will pay for and how much patients owe out of pocket.

The drug's oral, once-daily format without food or timing restrictions may also matter to patients who have avoided GLP-1 treatment because of needle aversion or the strict fasting rules tied to existing oral semaglutide ^[2][6]. Whether that convenience changes uptake once broader US insurance decisions are made is not yet known.

What happens next

NICE has not set a date for its second committee review of Foundayo, though the appraisal listing has an expected publication date of November 18, 2026 ^[1]. Foundayo also remains under review by European Union regulators, while the oral semaglutide pill from Novo Nordisk has already received a positive recommendation from the European Medicines Agency, with a final European Commission decision still pending ^[3].